Shopping Cart 0
Cart Subtotal
USD 0

Gene Therapy Market by Vector Type (Viral Vector and Non-viral Vector), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), and Application (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases): Global Opportunity Analysis and Industry Forecast, 2019-2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 5370

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 8995

Details

The global gene therapy market was valued at USD 393.35 million in 2018, and is estimated to reach USD 6,205.85 million by 2026, registering a CAGR of 34.8% from 2019 to 2026.
Gene therapy is a technique that involves the delivery of nucleic acid polymers into a patient's cells as a drug to treat diseases. It fixes a genetic problem at its source. The process involves modifying the protein either to change the genetic expression or to correct a mutation. The emergence of this technology meets the rise in needs for better diagnostics and targeted therapy tools. For instance, genetic engineering can be used to modify physical appearance, metabolism, physical capabilities, and mental abilities such as memory and intelligence. In addition, it is also used for infertility treatment. Gene therapy offers a ray of hope for patients, who either have no treatment options or show no benefits with drugs currently available. The ongoing success has strongly supported upcoming researches and has carved ways for enhancement of gene therapy.
Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells. Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is on an increase, despite the limited number of products that have successfully reached the market. In addition, benefits of gene therapy over conventional cancer therapies and increase in government support fuel the growth of the gene therapy market.
The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential. Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market. On the contrary, increase in the pipeline developments for gene therapy market are expected to provide lucrative opportunity during the forecast period.
The global gene therapy market is segmented based on vector type, gene type, application, and geography. Based on vector type, it is categorized into viral vector and non-viral vector. Viral vector is further segmented into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Non-viral vector is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. Based on gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others. Based on application, the market is divided into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY MARKET BENEFITS FOR STAKEHOLDERS
This report offers a detailed quantitative analysis of the current market trends from 2018 to 2026 to identify the prevailing opportunities.
The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Vector Type
Viral vector
o Retroviruses
o Lentiviruses
o Adenoviruses
o Adeno Associated Virus
o Herpes Simplex Virus
o Poxvirus
o Vaccinia Virus
o Others
Non-viral vector
o Naked/Plasmid Vectors
o Gene Gun
o Electroporation
o Lipofection
o Others
By Gene Type
Antigen
Cytokine
Tumor Suppressor
Suicide
Deficiency
Growth factors
Receptors
Others
By Application
Oncological Disorders
Rare Diseases
Cardiovascular Diseases
Neurological Disorders
Infectious disease
Other Diseases
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o UK
o France
o Spain
o Italy
o Rest of Europe
Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
LAMEA
o Brazil
o South Africa
o Saudi Arabia
o Rest of LAMEA
 
KEY PLAYERS PROFILED
Adaptimmune Therapeutics Plc.
Anchiano Therapeutics Ltd.
Achieve Life Sciences, Inc.
Adverum Biotechnologies, Inc.
Abeona Therapeutics Inc.
Applied Genetic Technologies Corporation
Arbutus Biopharma Corporation,
Audentes Therapeutics, Inc.
AveXis, Inc.
Bluebird Bio, Inc.
Celgene Corporation
CRISPR Therapeutics AG
Editas Medicine, Inc.
Editas Medicine, Inc.
GlaxoSmithKline Plc.
Intellia Therapeutics, Inc.
Merck & Co., Inc.
Novartis AG
REGENXBIO Inc.
Spark Therapeutics, Inc.
Sangamo Therapeutics, Inc.
Uniqure N. V.
Voyager Therapeutics, Inc
The other players of the gene therapy market include (companies not profiled in the report):
Amgen
Epeius Biotechnologies
Sanofi
Juno Therapeutics
Advantagene
READ MORE

Table Of Content

Scope

Chapter 1: Introduction

 

1.1. Report Description

1.2. Key Benefits

1.3. Key Market Segments

1.4. Research Methodology

 

1.4.1. Secondary Research

1.4.2. Primary Research

1.4.3. Analyst Tools And Models

 

Chapter 2: Executive Summary

 

2.1. Cxo Perspective

 

Chapter 3: Market Overview

 

3.1. Market Definition And Scope

3.2. Key Findings

 

3.2.1. Top Investment Pockets

3.2.2. Top Winning Strategies

 

3.3. Top Player Positioning, 2018

3.4. Porter'S Five Forces Analysis

3.5. Market Dynamics

 

3.5.1. Drivers

 

3.5.1.1. High Investment For R&D Activities Pertaining To Gene Therapy

3.5.1.2. Increase In Prevalence of Cancer

3.5.1.3. Growth In Awareness Regarding Gene Therapy

 

3.5.2. Restraints

 

3.5.2.1. High Cost Associated With Gene Therapies

3.5.2.2. Unwanted Immune Responses

 

3.5.3. Opportunities

 

3.5.3.1. Untapped Potential For Emerging Markets

 

Chapter 4: Gene Therapy Market, By Vector Type

 

4.1. Overview

 

4.1.1. Market Size And Forecast

 

4.2. Viral Vectors

 

4.2.1. Key Market Trends, Growth Factors, And Opportunities

4.2.2. Market Size And Forecast, By Region

4.2.3. Market Size And Forecast, By Type

4.2.4. Market Size And Forecast, By Country

4.2.5. Adenovirus

4.2.6. Lentivirus

4.2.7. Retrovirus

4.2.8. Adeno-Associated Virus

4.2.9. Herpes Simplex Virus

4.2.10. Poxvirus

4.2.11. Vaccinia Virus

4.2.12. Others

 

4.3. Non-Viral Techniques

 

4.3.1. Key Market Trends, Growth Factors, And Opportunities

4.3.2. Market Size And Forecast, By Region

4.3.3. Market Size And Forecast, By Type

4.3.4. Market Size And Forecast, By Country

4.3.5. Naked Plasmid Vector

4.3.6. Gene Gun

4.3.7. Electroporation

4.3.8. Lipofection

4.3.9. Others

 

Chapter 5: Gene Therapy Market, By Gene Type

 

5.1. Overview

 

5.1.1. Market Size And Forecast, Type

 

5.2. Antigen

 

5.2.1. Market Size And Forecast

5.2.2. Market Size And Forecast, By Country

 

5.3. Cytokine

 

5.3.1. Market Size And Forecast

5.3.2. Market Size And Forecast, By Country

 

5.4. Tumor Suppressor

 

5.4.1. Market Size And Forecast, By Region

5.4.2. Market Size And Forecast, By Country

 

5.5. Suicide Gene

 

5.5.1. Market Size And Forecast

5.5.2. Market Size And Forecast, By Country

 

5.6. Deficiency

 

5.6.1. Market Size And Forecast, By Region

5.6.2. Market Size And Forecast, By Country

 

5.7. Growth Factors

 

5.7.1. Market Size And Forecast, By Region

5.7.2. Market Size And Forecast, By Country

 

5.8. Receptors

 

5.8.1. Market Size And Forecast, By Region

5.8.2. Market Size And Forecast, By Country

 

5.9. Others

 

5.9.1. Market Size And Forecast, By Region

5.9.2. Market Size And Forecast, By Country

 

Chapter 6: Gene Therapy Market, By Application

 

6.1. Overview

 

6.1.1. Market Size And Forecast, By Application

 

6.2. Oncological Disorders

 

6.2.1. Market Size And Forecast, By Region

6.2.2. Market Size And Forecast, By Country

 

6.3. Rare Diseases

 

6.3.1. Market Size And Forecast, By Region

6.3.2. Market Size And Forecast, By Country

 

6.4. Cardiovascular Diseases

 

6.4.1. Market Size And Forecast, By Region

6.4.2. Market Size And Forecast, By Country

 

6.5. Neurological Disorders

 

6.5.1. Market Size And Forecast

6.5.2. Market Size And Forecast, By Country

 

6.6. Infectious Diseases

 

6.6.1. Market Size And Forecast, By Region

6.6.2. Market Size And Forecast, By Country

 

6.7. Other Diseases

 

6.7.1. Market Size And Forecast

6.7.2. Market Size And Forecast, By Country

 

Chapter 7: Gene Therapy Market, By Region

 

7.1. Overview

 

7.1.1. Market Size And Forecast

 

7.2. North America

 

7.2.1. Key Market Trends, Growth Factors, And Opportunities

7.2.2. Market Size And Forecast, By Country

7.2.3. Market Size And Forecast, By Vector Type

7.2.4. Market Size And Forecast, By Gene Type

7.2.5. Market Size And Forecast, By Application

 

7.2.5.1. U.S. Market Size And Forecast, By Vector Type

7.2.5.2. U.S. Market Size And Forecast, By Gene Type

7.2.5.3. U.S. Market Size And Forecast, By Application

7.2.5.4. Canada Market Size And Forecast, By Vector Type

7.2.5.5. Canada Market Size And Forecast, By Gene Type

7.2.5.6. Canada Market Size And Forecast, By Application

7.2.5.7. Mexico Market Size And Forecast, By Vector Type

7.2.5.8. Mexico Market Size And Forecast, By Gene Type

7.2.5.9. Mexico Market Size And Forecast, By Application

 

7.3. Europe

 

7.3.1. Key Market Trends, Growth Factors, And Opportunities

7.3.2. Market Size And Forecast, By Country

7.3.3. Market Size And Forecast, By Vector Type

7.3.4. Market Size And Forecast, By Gene Type

7.3.5. Market Size And Forecast, By Application

 

7.3.5.1. Germany Market Size And Forecast, By Vector Type

7.3.5.2. Germany Market Size And Forecast, By Gene Type

7.3.5.3. Germany Market Size And Forecast, By Application

7.3.5.4. France Market Size And Forecast, By Vector Type

7.3.5.5. France Market Size And Forecast, By Gene Type

7.3.5.6. France Market Size And Forecast, By Application

7.3.5.7. Uk Market Size And Forecast, By Vector Type

7.3.5.8. Uk Market Size And Forecast, By Gene Type

7.3.5.9. Uk Market Size And Forecast, By Application

7.3.5.10. Italy Market Size And Forecast, By Vector Type

7.3.5.11. Italy Market Size And Forecast, By Gene Type

7.3.5.12. Italy Market Size And Forecast, By Application

7.3.5.13. Spain Market Size And Forecast, By Vector Type

7.3.5.14. Spain Market Size And Forecast, By Gene Type

7.3.5.15. Spain Market Size And Forecast, By Application

7.3.5.16. Rest of Europe Market Size And Forecast, By Vector Type

7.3.5.17. Rest of Europe Market Size And Forecast, By Gene Type

7.3.5.18. Rest of Europe Market Size And Forecast, By Application

 

7.4. Asia-Pacific

 

7.4.1. Key Market Trends, Growth Factors, And Opportunities

7.4.2. Market Size And Forecast, By Country

7.4.3. Market Size And Forecast, By Vector Type

7.4.4. Market Size And Forecast, By Gene Type

7.4.5. Market Size And Forecast, By Application

 

7.4.5.1. Japan Market Size And Forecast, By Vector Type

7.4.5.2. Japan Market Size And Forecast, By Gene Type

7.4.5.3. Japan Market Size And Forecast, By Application

7.4.5.4. China Market Size And Forecast, By Vector Type

7.4.5.5. China Market Size And Forecast, By Gene Type

7.4.5.6. China Market Size And Forecast, By Application

7.4.5.7. India Market Size And Forecast, By Vector Type

7.4.5.8. India Market Size And Forecast, By Gene Type

7.4.5.9. India Market Size And Forecast, By Application

7.4.5.10. South Korea Market Size And Forecast, By Vector Type

7.4.5.11. South Korea Market Size And Forecast, By Gene Type

7.4.5.12. South Korea Market Size And Forecast, By Application

7.4.5.13. Rest of Asia-Pacific Market Size And Forecast, By Vector Type

7.4.5.14. Rest of Asia-Pacific Market Size And Forecast, By Gene Type

7.4.5.15. Rest of Asia-Pacific Market Size And Forecast, By Application

 

7.5. Lamea

 

7.5.1. Key Market Trends, Growth Factors, And Opportunities

7.5.2. Market Size And Forecast, By Country

7.5.3. Market Size And Forecast, By Vector Type

7.5.4. Market Size And Forecast, By Gene Type

7.5.5. Market Size And Forecast, By Application

 

7.5.5.1. Brazil Market Size And Forecast, By Vector Type

7.5.5.2. Brazil Market Size And Forecast, By Gene Type

7.5.5.3. Brazil Market Size And Forecast, By Application

7.5.5.4. South Africa Market Size And Forecast, By Vector Type

7.5.5.5. South Africa Market Size And Forecast, By Gene Type

7.5.5.6. South Africa Market Size And Forecast, By Application

7.5.5.7. Rest of Lamea Market Size And Forecast, By Vector Type

7.5.5.8. Rest of Lamea Market Size And Forecast, By Gene Type

7.5.5.9. Rest of Lamea Market Size And Forecast, By Application

 

Chapter 8: Company Profile

 

8.1. Adaptimmune Therapeutics Plc.

 

8.1.1. Company Overview

8.1.2. Company Snapshot

8.1.3. Operating Business Segments

8.1.4. Product Portfolio

8.1.5. Business Performance

8.1.6. Key Strategic Moves And Developments

 

8.2. Anchiano Therapeutics Ltd.

 

8.2.1. Company Overview

8.2.2. Company Snapshot

8.2.3. Operating Business Segments

8.2.4. Product Portfolio

 

8.3. Achieve Life Sciences, Inc.

 

8.3.1. Company Overview

8.3.2. Company Snapshot

8.3.3. Operating Business Segments

8.3.4. Product Portfolio

8.3.5. Key Strategic Moves And Developments

 

8.4. Adverum Biotechnologies, Inc.

 

8.4.1. Company Overview

8.4.2. Company Snapshot

8.4.3. Operating Business Segments

8.4.4. Product Portfolio

8.4.5. Key Strategic Moves And Developments

 

8.5. Abeona Therapeutics Inc.

 

8.5.1. Company Overview

8.5.2. Company Snapshot

8.5.3. Operating Business Segments

8.5.4. Product Portfolio

8.5.5. Business Performance

8.5.6. Key Strategic Moves And Developments

 

8.6. Applied Genetic Technologies Corporation

 

8.6.1. Company Overview

8.6.2. Company Snapshot

8.6.3. Operating Business Segments

8.6.4. Product Portfolio

8.6.5. Business Performance

8.6.6. Key Strategic Moves And Developments

 

8.7. Arbutus Biopharma Corporation

 

8.7.1. Company Overview

8.7.2. Company Snapshot

8.7.3. Product Portfolio

8.7.4. Business Performance

8.7.5. Key Strategic Moves And Developments

 

8.8. Audentes Therapeutics Inc.

 

8.8.1. Company Overview

8.8.2. Company Snapshot

8.8.3. Product Portfolio

8.8.4. Key Strategic Moves And Developments

 

8.9. Avexis Inc.

 

8.9.1. Company Overview

8.9.2. Company Snapshot

8.9.3. Product Portfolio

8.9.4. Key Strategic Moves And Developments

 

8.10. Bluebird Bio, Inc.

 

8.10.1. Company Overview

8.10.2. Company Snapshot

8.10.3. Operating Business Segments

8.10.4. Product Portfolio

8.10.5. Business Performance

8.10.6. Key Strategic Moves And Developments

 

8.11. Celgene Corporation

 

8.11.1. Company Overview

8.11.2. Company Snapshot

8.11.3. Operating Business Segments

8.11.4. Product Portfolio

8.11.5. Business Performance

8.11.6. Key Strategic Moves And Developments

 

8.12. Crispr Therapeutics Ag

 

8.12.1. Company Overview

8.12.2. Company Snapshot

8.12.3. Product Portfolio

8.12.4. Business Performance

8.12.5. Key Strategic Moves And Developments

 

8.13. Editas Medicine, Inc.

 

8.13.1. Company Overview

8.13.2. Company Snapshot

8.13.3. Operating Business Segments

8.13.4. Product Portfolio

8.13.5. Business Performance

8.13.6. Key Strategic Moves And Developments

 

8.14. Gilead Sciences, Inc.

 

8.14.1. Company Overview

8.14.2. Company Snapshot

8.14.3. Operating Business Segments

8.14.4. Product Portfolio

8.14.5. Business Performance

8.14.6. Key Strategic Moves And Developments

 

8.15. Glaxosmithkline Plc

 

8.15.1. Company Overview

8.15.2. Company Snapshot

8.15.3. Operating Business Segments

8.15.4. Product Portfolio

8.15.5. Business Performance

8.15.6. Key Strategic Moves And Developments

 

8.16. Intellia Therapeutics Inc.

 

8.16.1. Company Overview

8.16.2. Company Snapshot

8.16.3. Operating Business Segments

8.16.4. Product Portfolio

8.16.5. Business Performance

8.16.6. Key Strategic Moves And Developments

 

8.17. Merck & Co., Inc.

 

8.17.1. Company Overview

8.17.2. Company Snapshot

8.17.3. Operating Business Segments

8.17.4. Product Portfolio

8.17.5. Business Performance

8.17.6. Key Strategic Moves And Developments

 

8.18. Novartis Ag

 

8.18.1. Company Overview

8.18.2. Company Snapshot

8.18.3. Operating Business Segments

8.18.4. Product Portfolio

8.18.5. Business Performance

8.18.6. Key Strategic Moves And Developments

 

8.19. Regenxbio, Inc.

 

8.19.1. Company Overview

8.19.2. Company Snapshot

8.19.3. Product Portfolio

8.19.4. Business Performance

8.19.5. Key Strategic Moves And Developments

 

8.20. Spark Therapeutics, Inc.

 

8.20.1. Company Overview

8.20.2. Company Snapshot

8.20.3. Operating Business Segments

8.20.4. Product Portfolio

8.20.5. Business Performance

8.20.6. Key Strategic Moves And Developments

 

8.21. Sangamo Therapeutics, Inc.

 

8.21.1. Company Overview

8.21.2. Company Snapshot

8.21.3. Operating Business Segments

8.21.4. Product Portfolio

8.21.5. Business Performance

8.21.6. Key Strategic Moves And Developments

 

8.22. Uniqure N. V.

 

8.22.1. Company Overview

8.22.2. Company Snapshot

8.22.3. Operation Segments

8.22.4. Product Portfolio

8.22.5. Business Performance

8.22.6. Key Strategic Moves And Developments

 

8.23. Voyager Therapeutics, Inc.

 

8.23.1. Company Overview

8.23.2. Company Snapshot

8.23.3. Operating Business Segments

8.23.4. Product Portfolio

8.23.5. Business Performance

8.23.6. Key Strategic Moves And Developments


List Of Figure

List of Figures

 

Figure 01. Global Gene Therapy Market Segmentation

Figure 02. Top Investment Pockets: By Gene Type, 2018

Figure 03. Top Winning Strategies, By Year, 2016-2019*

Figure 04. Top Winning Strategies, By Development, 2016-2019* (%)

Figure 05. Top Winning Strategies, By Company, 2016-2019*

Figure 06. Top Player Positioning, 2018

Figure 07. Low Bargaining Power of Buyers

Figure 08. High Bargaining Power of Suppliers

Figure 09. High Threat of New Entrants

Figure 10. Moderate Threat of Substitution

Figure 11. High Competitive Rivalry

Figure 12. Restraints And Drivers: Global Gene Therapy Market

Figure 13. Comparative Regional Share Analysis of Gene Therapy Market For Viral Vectors, 2018 Vs 2026 (USD Million)

Figure 14. Comparative Analysis of Gene Therapy Market For Non-Viral Vectors, 2018 Vs 2026 (%)

Figure 15. Comparative Analysis of Antigen Gene Therapy Market, By Country, 2018 Vs 2026 (%)

Figure 16. Comparative Analysis of Cytokine Gene Therapy Market, By Country, 2018 Vs 2026 (%)

Figure 17. Comparative Analysis of Tumor Suppressor Gene Therapy Market, By Country, 2018 Vs 2026 (%)

Figure 18. Comparative Analysis of Suicide Gene Therapy Market, By Country, 2018 Vs 2026 (%)

Figure 19. Comparative Analysis of Deficiency Gene Therapy Market, By Country, 2018 Vs 2026 (%)

Figure 20. Comparative Analysis of Growth Factors Gene Therapy Market, By Country, 2018 Vs 2026(%)

Figure 21. Comparative Analysis of Receptors Gene Therapy Market, By Country, 2018 Vs 2026 (%)

Figure 22. Comparative Analysis of Gene Therapy Market For Other Gene Types, 2018 Vs 2026 (%)

Figure 23. Comparative Analysis of Gene Therapy Market For Oncological Disorders, 2018 Vs 2026 (%)

Figure 24. Comparative Analysis of Gene Therapy Market For Rare Diseases, 2018 Vs 2026 (%)

Figure 25. Comparative Analysis of Gene Therapy Market For Cardiovascular Diseases, 2018 Vs 2026 (%)

Figure 26. Comparative Analysis of Gene Therapy Market For Neurological Disorders, 2018 Vs 2026 (%)

Figure 27. Comparative Analysis of Gene Therapy Market For Infectious Diseases, 2018 Vs 2026 (%)

Figure 28. Comparative Analysis of Gene Therapy Market For Other Diseases, 2018 Vs 2026 (%)

Figure 29. Adaptimmune: Revenue, 2016-2018(USD Million)

Figure 30. Adaptimmune: Segmentation, 2016-2018(%)

Figure 31. Abeona Therapeutics Inc.: Net Sales, 2014-2016 (USD Million)

Figure 32. Applied Genetic Technologies Corporation: Net Sales, 2015-2017 (USD Million)

Figure 33. Arbutus: Net Sales, 2016-2018 (USD Million)

Figure 34. Bluebird Bio: Revenue, 2016-2018(USD Million)

Figure 35. Celgene: Revenue, 2016-2018(USD Million)

Figure 36. Celgene: Revenue Share By Product, 2018 (%)

Figure 37. Celgene: Revenue Share By Region, 2018 (%)

Figure 38. Crispr: Net Sales, 2016-2018 (USD Million)

Figure 39. Editas: Net Sales, 2016-2018 (USD Million)

Figure 40. Gilead: Revenue, 2016-2018(USD Million)

Figure 41. Gilead: Revenue Share By Region, 2018 (%)

Figure 42. Gsk: Revenue, 2016-2018(USD Million)

Figure 43. Gsk: Revenue Share By Segment, 2018 (%)

Figure 44. Gsk: Revenue Share By Region, 2018 (%)

Figure 45. Intellia: Net Sales, 2016-2018 (USD Million)

Figure 46. Merck: Revenue, 2016-2018(USD Million)

Figure 47. Merck: Revenue Share By Segment, 2018 (%)

Figure 48. Merck: Revenue Share By Region, 2018 (%)

Figure 49. Novartis: Revenue, 2016-2018 (USD Million)

Figure 50. Novartis: Revenue Share By Segment, 2018 (%)

Figure 51. Novartis: Revenue Share By Region, 2018 (%)

Figure 52. Regenxbio: Net Sales, 2016-2018 (USD Million)

Figure 53. Spark Therapeutics, Inc.: Revenue, 2016-2018 (USD Million)

Figure 54. Sangamo Therapeutics: Net Sales, 2016-2018 (USD Million)

Figure 55. Uniqure.: Net Sales, 2016-2018 (USD Million)

Figure 56. Voyager: Net Sales, 2016-2018 (USD Million)

 


List Of Table

List of Tables

 

Table 01. Late-Stage Clinical Data Events of Gene Therpy

Table 02. Gene Therapy Pipeline Volume, Preclinical Through Pre-Registration Phase, 1995-2018

Table 03. Global Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 04. Global Gene Therapy Market For Viral Vectors, By Region, 2018-2026 (USD Million)

Table 05. Global Gene Therapy Market For Viral Vectors, By Type, 2018-2026 (USD Million)

Table 06. Gene Therapy Market For Non-Viral Vectors, By Region, 2018-2026 (USD Million)

Table 07. Global Gene Therapy Market For Non-Viral Vectors, By Type, 2018-2026 (USD Million)

Table 08. Global Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 09. Antigen Gene Therapy Market, By Region, 2018-2026 (USD Million)

Table 10. Cytokine Gene Therapy Market, By Region, 2018-2026 (USD Million)

Table 11. Tumor Suppressor Gene Therapy Market, By Region, 2018-2026 (USD Million)

Table 12. Suicide Gene Therapy Market, By Region, 2018-2026 (USD Million)

Table 13. Deficiency Gene Therapy Market, By Region, 2018-2026 (USD Million)

Table 14. Growth Factors Gene Therapy Market, By Region, 2018-2026 (USD Million)

Table 15. Receptors Gene Therapy Market, By Region, 2018-2026 (USD Million)

Table 16. Gene Therapy Market For Other Gene Types, By Region, 2018-2026 (USD Million)

Table 17. Global Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 18. Gene Therapy Market For Oncological Disorders, By Region, 2018-2026 (USD Million)

Table 19. Gene Therapy Market For Rare Diseases, By Region, 2018-2026 (USD Million)

Table 20. Gene Therapy Market For Cardiovascular Diseases, By Region, 2018-2026 (USD Million)

Table 21. Gene Therapy Market For Neurological Disorders, By Region, 2018-2026 (USD Million)

Table 22. Gene Therapy Market For Infectious Diseases, By Region, 2018-2026 (USD Million)

Table 23. Gene Therapy Market For Other Diseases, By Region, 2018-2026 (USD Million)

Table 24. Gene Therapy Market, By Region, 2018-2026 (USD Million)

Table 25. North America Gene Therapy Market, By Country, 2018-2026 (USD Million)

Table 26. North America Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 27. North America Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 28. North America Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 29. U.S. Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 30. U.S. Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 31. U.S. Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 32. Canada Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 33. Canada Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 34. Canada Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 35. Mexico Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 36. Mexico Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 37. Mexico Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 38. Europe Gene Therapy Market, By Country, 2018-2026 (USD Million)

Table 39. Europe Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 40. Europe Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 41. Europe Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 42. Germany Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 43. Germany Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 44. Germany Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 45. France Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 46. France Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 47. France Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 48. Uk Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 49. Uk Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 50. Uk Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 51. Italy Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 52. Italy Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 53. Italy Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 54. Spain Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 55. Spain Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 56. Spain Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 57. Rest of Europe Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 58. Rest of Europe Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 59. Rest of Europe Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 60. Asia-Pacific Gene Therapy Market, By Country, 2018-2026 (USD Million)

Table 61. Asia-Pacific Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 62. Asia-Pacific Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 63. Asia-Pacific Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 64. Japan Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 65. Japan Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 66. Japan Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 67. China Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 68. China Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 69. China Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 70. India Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 71. India Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 72. India Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 73. South Korea Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 74. South Korea Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 75. South Korea Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 76. Rest of Asia-Pacific Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 77. Rest of Asia-Pacific Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 78. Rest of Asia-Pacific Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 79. Lamea Gene Therapy Market, By Country, 2018-2026 (USD Million)

Table 80. Lamea Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 81. Lamea Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 82. Lamea Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 83. Brazil Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 84. Brazil Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 85. Brazil Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 86. South Africa Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 87. South Africa Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 88. South Africa Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 89. Rest of Lamea Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 90. Rest of Lamea Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 91. Rest of Lamea Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 92. Adaptimmune: Company Snapshot

Table 93. Adaptimmune: Business Unit

Table 94. Adaptimmune.: Product Portfolio

Table 95. Anchiano Therapeutics: Company Snapshot

Table 96. Anchiano Therapeutics: Product Category

Table 97. Anchiano Therapeutics: Product Portfolio

Table 98. Achieve Life Sciences.: Company Snapshot

Table 99. Achieve Life Sciences.: Operating Segments

Table 100. Achieve Life Sciences: Product Portfolio

Table 101. Adverum Biotechnologies, Inc.: Company Snapshot

Table 102. Adverum Biotechnologies, Inc.: Product Category

Table 103. Adverum Biotechnologies, Inc.: Product Portfolio

Table 104. Abeona Therapeutics Inc.: Company Snapshot

Table 105. Abeona Therapeutics Inc.: Product Category

Table 106. Abeona Therapeutics Inc.: Product Portfolio

Table 107. Applied Genetic Technologies Corporation: Company Snapshot

Table 108. Applied Genetic Technologies Corporation: Operating Segments

Table 109. Applied Genetic Technologies Corporation: Product Portfolio

Table 110. Arbutus: Company Snapshot

Table 111. Arbutus: Product Portfolio

Table 112. Audentes: Company Snapshot

Table 113. Audentes: Product Portfolio

Table 114. Avexis: Company Snapshot

Table 115. Avexis: Product Portfolio

Table 116. Bluebird Bio : Company Snapshot

Table 117. Bluebird Bio: Product Category

Table 118. Bluebird Bio.: Product Portfolio

Table 119. Celgene: Company Snapshot

Table 120. Celgene: Operating Segments

Table 121. Celgene: Product Portfolio

Table 122. Crispr: Company Snapshot

Table 123. Crispr: Product Portfolio

Table 124. Editas.: Company Snapshot

Table 125. Editas: Product Portfolio

Table 126. Gilead: Company Snapshot

Table 127. Gilead: Operating Segments

Table 128. Gilead: Product Portfolio

Table 129. Gsk.: Company Snapshot

Table 130. Gsk: Operating Segments

Table 131. Gsk: Product Portfolio

Table 132. Intellia: Company Snapshot

Table 133. Intellia: Product Portfolio

Table 134. Merck: Company Snapshot

Table 135. Merck: Operating Segments

Table 136. Merck.: Product Portfolio

Table 137. Novartis: Company Snapshot

Table 138. Novartis: Operating Division

Table 139. Novartis: Product Portfolio

Table 140. Regenxbio: Company Snapshot

Table 141. Regenxbio: Product Portfolio

Table 142. Spark Therapeutics: Company Snapshot

Table 143. Spark Therapeutics, Inc.: Product Category

Table 144. Spark Therapeutics, Inc.: Product Portfolio

Table 145. Sangamo Therapeutics: Company Snapshot

Table 146. Sangamo Therapeutics: Operating Business Segments

Table 147. Sangamo Therapeutics: Product Portfolio

Table 148. Uniqure: Company Snapshot

Table 149. Uniqure: Product Business Segment

Table 150. Uniqure.: Product Portfolio

Table 151. Voyager.: Company Snapshot

Table 152. Voyager : Product Business Segments

Table 153. Voyager.: Product Portfolio

Licence Rights

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Adaptimmune Therapeutics Plc., Anchiano Therapeutics Ltd., Achieve Life Sciences, Inc., Adverum Biotechnologies, Inc., Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Arbutus Biopharma Corporation, Audentes Therapeutics, Inc., AveXis, Inc., Bluebird Bio, Inc., Celgene Corporation, CRISPR Therapeutics AG, Editas Medicine, Inc., Editas Medicine, Inc., GlaxoSmithKline Plc., Intellia Therapeutics, Inc., Merck & Co., Inc., Novartis AG, REGENXBIO Inc., Spark Therapeutics, Inc., Sangamo Therapeutics, Inc., Uniqure N. V., Voyager Therapeutics, Inc.

Company Profile

Company Profile Title

The global gene therapy market was valued at USD 393.35 million in 2018, and is estimated to reach USD 6,205.85 million by 2026, registering a CAGR of 34.8% from 2019 to 2026.
Gene therapy is a technique that involves the delivery of nucleic acid polymers into a patient's cells as a drug to treat diseases. It fixes a genetic problem at its source. The process involves modifying the protein either to change the genetic expression or to correct a mutation. The emergence of this technology meets the rise in needs for better diagnostics and targeted therapy tools. For instance, genetic engineering can be used to modify physical appearance, metabolism, physical capabilities, and mental abilities such as memory and intelligence. In addition, it is also used for infertility treatment. Gene therapy offers a ray of hope for patients, who either have no treatment options or show no benefits with drugs currently available. The ongoing success has strongly supported upcoming researches and has carved ways for enhancement of gene therapy.
Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells. Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is on an increase, despite the limited number of products that have successfully reached the market. In addition, benefits of gene therapy over conventional cancer therapies and increase in government support fuel the growth of the gene therapy market.
The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential. Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market. On the contrary, increase in the pipeline developments for gene therapy market are expected to provide lucrative opportunity during the forecast period.
The global gene therapy market is segmented based on vector type, gene type, application, and geography. Based on vector type, it is categorized into viral vector and non-viral vector. Viral vector is further segmented into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Non-viral vector is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. Based on gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others. Based on application, the market is divided into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY MARKET BENEFITS FOR STAKEHOLDERS
This report offers a detailed quantitative analysis of the current market trends from 2018 to 2026 to identify the prevailing opportunities.
The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Vector Type
Viral vector
o Retroviruses
o Lentiviruses
o Adenoviruses
o Adeno Associated Virus
o Herpes Simplex Virus
o Poxvirus
o Vaccinia Virus
o Others
Non-viral vector
o Naked/Plasmid Vectors
o Gene Gun
o Electroporation
o Lipofection
o Others
By Gene Type
Antigen
Cytokine
Tumor Suppressor
Suicide
Deficiency
Growth factors
Receptors
Others
By Application
Oncological Disorders
Rare Diseases
Cardiovascular Diseases
Neurological Disorders
Infectious disease
Other Diseases
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o UK
o France
o Spain
o Italy
o Rest of Europe
Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
LAMEA
o Brazil
o South Africa
o Saudi Arabia
o Rest of LAMEA
 
KEY PLAYERS PROFILED
Adaptimmune Therapeutics Plc.
Anchiano Therapeutics Ltd.
Achieve Life Sciences, Inc.
Adverum Biotechnologies, Inc.
Abeona Therapeutics Inc.
Applied Genetic Technologies Corporation
Arbutus Biopharma Corporation,
Audentes Therapeutics, Inc.
AveXis, Inc.
Bluebird Bio, Inc.
Celgene Corporation
CRISPR Therapeutics AG
Editas Medicine, Inc.
Editas Medicine, Inc.
GlaxoSmithKline Plc.
Intellia Therapeutics, Inc.
Merck & Co., Inc.
Novartis AG
REGENXBIO Inc.
Spark Therapeutics, Inc.
Sangamo Therapeutics, Inc.
Uniqure N. V.
Voyager Therapeutics, Inc
The other players of the gene therapy market include (companies not profiled in the report):
Amgen
Epeius Biotechnologies
Sanofi
Juno Therapeutics
Advantagene
READ MORE

Scope

Chapter 1: Introduction

 

1.1. Report Description

1.2. Key Benefits

1.3. Key Market Segments

1.4. Research Methodology

 

1.4.1. Secondary Research

1.4.2. Primary Research

1.4.3. Analyst Tools And Models

 

Chapter 2: Executive Summary

 

2.1. Cxo Perspective

 

Chapter 3: Market Overview

 

3.1. Market Definition And Scope

3.2. Key Findings

 

3.2.1. Top Investment Pockets

3.2.2. Top Winning Strategies

 

3.3. Top Player Positioning, 2018

3.4. Porter'S Five Forces Analysis

3.5. Market Dynamics

 

3.5.1. Drivers

 

3.5.1.1. High Investment For R&D Activities Pertaining To Gene Therapy

3.5.1.2. Increase In Prevalence of Cancer

3.5.1.3. Growth In Awareness Regarding Gene Therapy

 

3.5.2. Restraints

 

3.5.2.1. High Cost Associated With Gene Therapies

3.5.2.2. Unwanted Immune Responses

 

3.5.3. Opportunities

 

3.5.3.1. Untapped Potential For Emerging Markets

 

Chapter 4: Gene Therapy Market, By Vector Type

 

4.1. Overview

 

4.1.1. Market Size And Forecast

 

4.2. Viral Vectors

 

4.2.1. Key Market Trends, Growth Factors, And Opportunities

4.2.2. Market Size And Forecast, By Region

4.2.3. Market Size And Forecast, By Type

4.2.4. Market Size And Forecast, By Country

4.2.5. Adenovirus

4.2.6. Lentivirus

4.2.7. Retrovirus

4.2.8. Adeno-Associated Virus

4.2.9. Herpes Simplex Virus

4.2.10. Poxvirus

4.2.11. Vaccinia Virus

4.2.12. Others

 

4.3. Non-Viral Techniques

 

4.3.1. Key Market Trends, Growth Factors, And Opportunities

4.3.2. Market Size And Forecast, By Region

4.3.3. Market Size And Forecast, By Type

4.3.4. Market Size And Forecast, By Country

4.3.5. Naked Plasmid Vector

4.3.6. Gene Gun

4.3.7. Electroporation

4.3.8. Lipofection

4.3.9. Others

 

Chapter 5: Gene Therapy Market, By Gene Type

 

5.1. Overview

 

5.1.1. Market Size And Forecast, Type

 

5.2. Antigen

 

5.2.1. Market Size And Forecast

5.2.2. Market Size And Forecast, By Country

 

5.3. Cytokine

 

5.3.1. Market Size And Forecast

5.3.2. Market Size And Forecast, By Country

 

5.4. Tumor Suppressor

 

5.4.1. Market Size And Forecast, By Region

5.4.2. Market Size And Forecast, By Country

 

5.5. Suicide Gene

 

5.5.1. Market Size And Forecast

5.5.2. Market Size And Forecast, By Country

 

5.6. Deficiency

 

5.6.1. Market Size And Forecast, By Region

5.6.2. Market Size And Forecast, By Country

 

5.7. Growth Factors

 

5.7.1. Market Size And Forecast, By Region

5.7.2. Market Size And Forecast, By Country

 

5.8. Receptors

 

5.8.1. Market Size And Forecast, By Region

5.8.2. Market Size And Forecast, By Country

 

5.9. Others

 

5.9.1. Market Size And Forecast, By Region

5.9.2. Market Size And Forecast, By Country

 

Chapter 6: Gene Therapy Market, By Application

 

6.1. Overview

 

6.1.1. Market Size And Forecast, By Application

 

6.2. Oncological Disorders

 

6.2.1. Market Size And Forecast, By Region

6.2.2. Market Size And Forecast, By Country

 

6.3. Rare Diseases

 

6.3.1. Market Size And Forecast, By Region

6.3.2. Market Size And Forecast, By Country

 

6.4. Cardiovascular Diseases

 

6.4.1. Market Size And Forecast, By Region

6.4.2. Market Size And Forecast, By Country

 

6.5. Neurological Disorders

 

6.5.1. Market Size And Forecast

6.5.2. Market Size And Forecast, By Country

 

6.6. Infectious Diseases

 

6.6.1. Market Size And Forecast, By Region

6.6.2. Market Size And Forecast, By Country

 

6.7. Other Diseases

 

6.7.1. Market Size And Forecast

6.7.2. Market Size And Forecast, By Country

 

Chapter 7: Gene Therapy Market, By Region

 

7.1. Overview

 

7.1.1. Market Size And Forecast

 

7.2. North America

 

7.2.1. Key Market Trends, Growth Factors, And Opportunities

7.2.2. Market Size And Forecast, By Country

7.2.3. Market Size And Forecast, By Vector Type

7.2.4. Market Size And Forecast, By Gene Type

7.2.5. Market Size And Forecast, By Application

 

7.2.5.1. U.S. Market Size And Forecast, By Vector Type

7.2.5.2. U.S. Market Size And Forecast, By Gene Type

7.2.5.3. U.S. Market Size And Forecast, By Application

7.2.5.4. Canada Market Size And Forecast, By Vector Type

7.2.5.5. Canada Market Size And Forecast, By Gene Type

7.2.5.6. Canada Market Size And Forecast, By Application

7.2.5.7. Mexico Market Size And Forecast, By Vector Type

7.2.5.8. Mexico Market Size And Forecast, By Gene Type

7.2.5.9. Mexico Market Size And Forecast, By Application

 

7.3. Europe

 

7.3.1. Key Market Trends, Growth Factors, And Opportunities

7.3.2. Market Size And Forecast, By Country

7.3.3. Market Size And Forecast, By Vector Type

7.3.4. Market Size And Forecast, By Gene Type

7.3.5. Market Size And Forecast, By Application

 

7.3.5.1. Germany Market Size And Forecast, By Vector Type

7.3.5.2. Germany Market Size And Forecast, By Gene Type

7.3.5.3. Germany Market Size And Forecast, By Application

7.3.5.4. France Market Size And Forecast, By Vector Type

7.3.5.5. France Market Size And Forecast, By Gene Type

7.3.5.6. France Market Size And Forecast, By Application

7.3.5.7. Uk Market Size And Forecast, By Vector Type

7.3.5.8. Uk Market Size And Forecast, By Gene Type

7.3.5.9. Uk Market Size And Forecast, By Application

7.3.5.10. Italy Market Size And Forecast, By Vector Type

7.3.5.11. Italy Market Size And Forecast, By Gene Type

7.3.5.12. Italy Market Size And Forecast, By Application

7.3.5.13. Spain Market Size And Forecast, By Vector Type

7.3.5.14. Spain Market Size And Forecast, By Gene Type

7.3.5.15. Spain Market Size And Forecast, By Application

7.3.5.16. Rest of Europe Market Size And Forecast, By Vector Type

7.3.5.17. Rest of Europe Market Size And Forecast, By Gene Type

7.3.5.18. Rest of Europe Market Size And Forecast, By Application

 

7.4. Asia-Pacific

 

7.4.1. Key Market Trends, Growth Factors, And Opportunities

7.4.2. Market Size And Forecast, By Country

7.4.3. Market Size And Forecast, By Vector Type

7.4.4. Market Size And Forecast, By Gene Type

7.4.5. Market Size And Forecast, By Application

 

7.4.5.1. Japan Market Size And Forecast, By Vector Type

7.4.5.2. Japan Market Size And Forecast, By Gene Type

7.4.5.3. Japan Market Size And Forecast, By Application

7.4.5.4. China Market Size And Forecast, By Vector Type

7.4.5.5. China Market Size And Forecast, By Gene Type

7.4.5.6. China Market Size And Forecast, By Application

7.4.5.7. India Market Size And Forecast, By Vector Type

7.4.5.8. India Market Size And Forecast, By Gene Type

7.4.5.9. India Market Size And Forecast, By Application

7.4.5.10. South Korea Market Size And Forecast, By Vector Type

7.4.5.11. South Korea Market Size And Forecast, By Gene Type

7.4.5.12. South Korea Market Size And Forecast, By Application

7.4.5.13. Rest of Asia-Pacific Market Size And Forecast, By Vector Type

7.4.5.14. Rest of Asia-Pacific Market Size And Forecast, By Gene Type

7.4.5.15. Rest of Asia-Pacific Market Size And Forecast, By Application

 

7.5. Lamea

 

7.5.1. Key Market Trends, Growth Factors, And Opportunities

7.5.2. Market Size And Forecast, By Country

7.5.3. Market Size And Forecast, By Vector Type

7.5.4. Market Size And Forecast, By Gene Type

7.5.5. Market Size And Forecast, By Application

 

7.5.5.1. Brazil Market Size And Forecast, By Vector Type

7.5.5.2. Brazil Market Size And Forecast, By Gene Type

7.5.5.3. Brazil Market Size And Forecast, By Application

7.5.5.4. South Africa Market Size And Forecast, By Vector Type

7.5.5.5. South Africa Market Size And Forecast, By Gene Type

7.5.5.6. South Africa Market Size And Forecast, By Application

7.5.5.7. Rest of Lamea Market Size And Forecast, By Vector Type

7.5.5.8. Rest of Lamea Market Size And Forecast, By Gene Type

7.5.5.9. Rest of Lamea Market Size And Forecast, By Application

 

Chapter 8: Company Profile

 

8.1. Adaptimmune Therapeutics Plc.

 

8.1.1. Company Overview

8.1.2. Company Snapshot

8.1.3. Operating Business Segments

8.1.4. Product Portfolio

8.1.5. Business Performance

8.1.6. Key Strategic Moves And Developments

 

8.2. Anchiano Therapeutics Ltd.

 

8.2.1. Company Overview

8.2.2. Company Snapshot

8.2.3. Operating Business Segments

8.2.4. Product Portfolio

 

8.3. Achieve Life Sciences, Inc.

 

8.3.1. Company Overview

8.3.2. Company Snapshot

8.3.3. Operating Business Segments

8.3.4. Product Portfolio

8.3.5. Key Strategic Moves And Developments

 

8.4. Adverum Biotechnologies, Inc.

 

8.4.1. Company Overview

8.4.2. Company Snapshot

8.4.3. Operating Business Segments

8.4.4. Product Portfolio

8.4.5. Key Strategic Moves And Developments

 

8.5. Abeona Therapeutics Inc.

 

8.5.1. Company Overview

8.5.2. Company Snapshot

8.5.3. Operating Business Segments

8.5.4. Product Portfolio

8.5.5. Business Performance

8.5.6. Key Strategic Moves And Developments

 

8.6. Applied Genetic Technologies Corporation

 

8.6.1. Company Overview

8.6.2. Company Snapshot

8.6.3. Operating Business Segments

8.6.4. Product Portfolio

8.6.5. Business Performance

8.6.6. Key Strategic Moves And Developments

 

8.7. Arbutus Biopharma Corporation

 

8.7.1. Company Overview

8.7.2. Company Snapshot

8.7.3. Product Portfolio

8.7.4. Business Performance

8.7.5. Key Strategic Moves And Developments

 

8.8. Audentes Therapeutics Inc.

 

8.8.1. Company Overview

8.8.2. Company Snapshot

8.8.3. Product Portfolio

8.8.4. Key Strategic Moves And Developments

 

8.9. Avexis Inc.

 

8.9.1. Company Overview

8.9.2. Company Snapshot

8.9.3. Product Portfolio

8.9.4. Key Strategic Moves And Developments

 

8.10. Bluebird Bio, Inc.

 

8.10.1. Company Overview

8.10.2. Company Snapshot

8.10.3. Operating Business Segments

8.10.4. Product Portfolio

8.10.5. Business Performance

8.10.6. Key Strategic Moves And Developments

 

8.11. Celgene Corporation

 

8.11.1. Company Overview

8.11.2. Company Snapshot

8.11.3. Operating Business Segments

8.11.4. Product Portfolio

8.11.5. Business Performance

8.11.6. Key Strategic Moves And Developments

 

8.12. Crispr Therapeutics Ag

 

8.12.1. Company Overview

8.12.2. Company Snapshot

8.12.3. Product Portfolio

8.12.4. Business Performance

8.12.5. Key Strategic Moves And Developments

 

8.13. Editas Medicine, Inc.

 

8.13.1. Company Overview

8.13.2. Company Snapshot

8.13.3. Operating Business Segments

8.13.4. Product Portfolio

8.13.5. Business Performance

8.13.6. Key Strategic Moves And Developments

 

8.14. Gilead Sciences, Inc.

 

8.14.1. Company Overview

8.14.2. Company Snapshot

8.14.3. Operating Business Segments

8.14.4. Product Portfolio

8.14.5. Business Performance

8.14.6. Key Strategic Moves And Developments

 

8.15. Glaxosmithkline Plc

 

8.15.1. Company Overview

8.15.2. Company Snapshot

8.15.3. Operating Business Segments

8.15.4. Product Portfolio

8.15.5. Business Performance

8.15.6. Key Strategic Moves And Developments

 

8.16. Intellia Therapeutics Inc.

 

8.16.1. Company Overview

8.16.2. Company Snapshot

8.16.3. Operating Business Segments

8.16.4. Product Portfolio

8.16.5. Business Performance

8.16.6. Key Strategic Moves And Developments

 

8.17. Merck & Co., Inc.

 

8.17.1. Company Overview

8.17.2. Company Snapshot

8.17.3. Operating Business Segments

8.17.4. Product Portfolio

8.17.5. Business Performance

8.17.6. Key Strategic Moves And Developments

 

8.18. Novartis Ag

 

8.18.1. Company Overview

8.18.2. Company Snapshot

8.18.3. Operating Business Segments

8.18.4. Product Portfolio

8.18.5. Business Performance

8.18.6. Key Strategic Moves And Developments

 

8.19. Regenxbio, Inc.

 

8.19.1. Company Overview

8.19.2. Company Snapshot

8.19.3. Product Portfolio

8.19.4. Business Performance

8.19.5. Key Strategic Moves And Developments

 

8.20. Spark Therapeutics, Inc.

 

8.20.1. Company Overview

8.20.2. Company Snapshot

8.20.3. Operating Business Segments

8.20.4. Product Portfolio

8.20.5. Business Performance

8.20.6. Key Strategic Moves And Developments

 

8.21. Sangamo Therapeutics, Inc.

 

8.21.1. Company Overview

8.21.2. Company Snapshot

8.21.3. Operating Business Segments

8.21.4. Product Portfolio

8.21.5. Business Performance

8.21.6. Key Strategic Moves And Developments

 

8.22. Uniqure N. V.

 

8.22.1. Company Overview

8.22.2. Company Snapshot

8.22.3. Operation Segments

8.22.4. Product Portfolio

8.22.5. Business Performance

8.22.6. Key Strategic Moves And Developments

 

8.23. Voyager Therapeutics, Inc.

 

8.23.1. Company Overview

8.23.2. Company Snapshot

8.23.3. Operating Business Segments

8.23.4. Product Portfolio

8.23.5. Business Performance

8.23.6. Key Strategic Moves And Developments


List Of Figure

List of Figures

 

Figure 01. Global Gene Therapy Market Segmentation

Figure 02. Top Investment Pockets: By Gene Type, 2018

Figure 03. Top Winning Strategies, By Year, 2016-2019*

Figure 04. Top Winning Strategies, By Development, 2016-2019* (%)

Figure 05. Top Winning Strategies, By Company, 2016-2019*

Figure 06. Top Player Positioning, 2018

Figure 07. Low Bargaining Power of Buyers

Figure 08. High Bargaining Power of Suppliers

Figure 09. High Threat of New Entrants

Figure 10. Moderate Threat of Substitution

Figure 11. High Competitive Rivalry

Figure 12. Restraints And Drivers: Global Gene Therapy Market

Figure 13. Comparative Regional Share Analysis of Gene Therapy Market For Viral Vectors, 2018 Vs 2026 (USD Million)

Figure 14. Comparative Analysis of Gene Therapy Market For Non-Viral Vectors, 2018 Vs 2026 (%)

Figure 15. Comparative Analysis of Antigen Gene Therapy Market, By Country, 2018 Vs 2026 (%)

Figure 16. Comparative Analysis of Cytokine Gene Therapy Market, By Country, 2018 Vs 2026 (%)

Figure 17. Comparative Analysis of Tumor Suppressor Gene Therapy Market, By Country, 2018 Vs 2026 (%)

Figure 18. Comparative Analysis of Suicide Gene Therapy Market, By Country, 2018 Vs 2026 (%)

Figure 19. Comparative Analysis of Deficiency Gene Therapy Market, By Country, 2018 Vs 2026 (%)

Figure 20. Comparative Analysis of Growth Factors Gene Therapy Market, By Country, 2018 Vs 2026(%)

Figure 21. Comparative Analysis of Receptors Gene Therapy Market, By Country, 2018 Vs 2026 (%)

Figure 22. Comparative Analysis of Gene Therapy Market For Other Gene Types, 2018 Vs 2026 (%)

Figure 23. Comparative Analysis of Gene Therapy Market For Oncological Disorders, 2018 Vs 2026 (%)

Figure 24. Comparative Analysis of Gene Therapy Market For Rare Diseases, 2018 Vs 2026 (%)

Figure 25. Comparative Analysis of Gene Therapy Market For Cardiovascular Diseases, 2018 Vs 2026 (%)

Figure 26. Comparative Analysis of Gene Therapy Market For Neurological Disorders, 2018 Vs 2026 (%)

Figure 27. Comparative Analysis of Gene Therapy Market For Infectious Diseases, 2018 Vs 2026 (%)

Figure 28. Comparative Analysis of Gene Therapy Market For Other Diseases, 2018 Vs 2026 (%)

Figure 29. Adaptimmune: Revenue, 2016-2018(USD Million)

Figure 30. Adaptimmune: Segmentation, 2016-2018(%)

Figure 31. Abeona Therapeutics Inc.: Net Sales, 2014-2016 (USD Million)

Figure 32. Applied Genetic Technologies Corporation: Net Sales, 2015-2017 (USD Million)

Figure 33. Arbutus: Net Sales, 2016-2018 (USD Million)

Figure 34. Bluebird Bio: Revenue, 2016-2018(USD Million)

Figure 35. Celgene: Revenue, 2016-2018(USD Million)

Figure 36. Celgene: Revenue Share By Product, 2018 (%)

Figure 37. Celgene: Revenue Share By Region, 2018 (%)

Figure 38. Crispr: Net Sales, 2016-2018 (USD Million)

Figure 39. Editas: Net Sales, 2016-2018 (USD Million)

Figure 40. Gilead: Revenue, 2016-2018(USD Million)

Figure 41. Gilead: Revenue Share By Region, 2018 (%)

Figure 42. Gsk: Revenue, 2016-2018(USD Million)

Figure 43. Gsk: Revenue Share By Segment, 2018 (%)

Figure 44. Gsk: Revenue Share By Region, 2018 (%)

Figure 45. Intellia: Net Sales, 2016-2018 (USD Million)

Figure 46. Merck: Revenue, 2016-2018(USD Million)

Figure 47. Merck: Revenue Share By Segment, 2018 (%)

Figure 48. Merck: Revenue Share By Region, 2018 (%)

Figure 49. Novartis: Revenue, 2016-2018 (USD Million)

Figure 50. Novartis: Revenue Share By Segment, 2018 (%)

Figure 51. Novartis: Revenue Share By Region, 2018 (%)

Figure 52. Regenxbio: Net Sales, 2016-2018 (USD Million)

Figure 53. Spark Therapeutics, Inc.: Revenue, 2016-2018 (USD Million)

Figure 54. Sangamo Therapeutics: Net Sales, 2016-2018 (USD Million)

Figure 55. Uniqure.: Net Sales, 2016-2018 (USD Million)

Figure 56. Voyager: Net Sales, 2016-2018 (USD Million)

 


List Of Table

List of Tables

 

Table 01. Late-Stage Clinical Data Events of Gene Therpy

Table 02. Gene Therapy Pipeline Volume, Preclinical Through Pre-Registration Phase, 1995-2018

Table 03. Global Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 04. Global Gene Therapy Market For Viral Vectors, By Region, 2018-2026 (USD Million)

Table 05. Global Gene Therapy Market For Viral Vectors, By Type, 2018-2026 (USD Million)

Table 06. Gene Therapy Market For Non-Viral Vectors, By Region, 2018-2026 (USD Million)

Table 07. Global Gene Therapy Market For Non-Viral Vectors, By Type, 2018-2026 (USD Million)

Table 08. Global Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 09. Antigen Gene Therapy Market, By Region, 2018-2026 (USD Million)

Table 10. Cytokine Gene Therapy Market, By Region, 2018-2026 (USD Million)

Table 11. Tumor Suppressor Gene Therapy Market, By Region, 2018-2026 (USD Million)

Table 12. Suicide Gene Therapy Market, By Region, 2018-2026 (USD Million)

Table 13. Deficiency Gene Therapy Market, By Region, 2018-2026 (USD Million)

Table 14. Growth Factors Gene Therapy Market, By Region, 2018-2026 (USD Million)

Table 15. Receptors Gene Therapy Market, By Region, 2018-2026 (USD Million)

Table 16. Gene Therapy Market For Other Gene Types, By Region, 2018-2026 (USD Million)

Table 17. Global Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 18. Gene Therapy Market For Oncological Disorders, By Region, 2018-2026 (USD Million)

Table 19. Gene Therapy Market For Rare Diseases, By Region, 2018-2026 (USD Million)

Table 20. Gene Therapy Market For Cardiovascular Diseases, By Region, 2018-2026 (USD Million)

Table 21. Gene Therapy Market For Neurological Disorders, By Region, 2018-2026 (USD Million)

Table 22. Gene Therapy Market For Infectious Diseases, By Region, 2018-2026 (USD Million)

Table 23. Gene Therapy Market For Other Diseases, By Region, 2018-2026 (USD Million)

Table 24. Gene Therapy Market, By Region, 2018-2026 (USD Million)

Table 25. North America Gene Therapy Market, By Country, 2018-2026 (USD Million)

Table 26. North America Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 27. North America Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 28. North America Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 29. U.S. Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 30. U.S. Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 31. U.S. Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 32. Canada Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 33. Canada Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 34. Canada Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 35. Mexico Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 36. Mexico Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 37. Mexico Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 38. Europe Gene Therapy Market, By Country, 2018-2026 (USD Million)

Table 39. Europe Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 40. Europe Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 41. Europe Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 42. Germany Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 43. Germany Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 44. Germany Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 45. France Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 46. France Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 47. France Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 48. Uk Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 49. Uk Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 50. Uk Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 51. Italy Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 52. Italy Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 53. Italy Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 54. Spain Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 55. Spain Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 56. Spain Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 57. Rest of Europe Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 58. Rest of Europe Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 59. Rest of Europe Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 60. Asia-Pacific Gene Therapy Market, By Country, 2018-2026 (USD Million)

Table 61. Asia-Pacific Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 62. Asia-Pacific Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 63. Asia-Pacific Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 64. Japan Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 65. Japan Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 66. Japan Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 67. China Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 68. China Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 69. China Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 70. India Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 71. India Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 72. India Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 73. South Korea Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 74. South Korea Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 75. South Korea Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 76. Rest of Asia-Pacific Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 77. Rest of Asia-Pacific Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 78. Rest of Asia-Pacific Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 79. Lamea Gene Therapy Market, By Country, 2018-2026 (USD Million)

Table 80. Lamea Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 81. Lamea Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 82. Lamea Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 83. Brazil Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 84. Brazil Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 85. Brazil Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 86. South Africa Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 87. South Africa Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 88. South Africa Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 89. Rest of Lamea Gene Therapy Market, By Vector Type, 2018-2026 (USD Million)

Table 90. Rest of Lamea Gene Therapy Market, By Gene Type, 2018-2026 (USD Million)

Table 91. Rest of Lamea Gene Therapy Market, By Application, 2018-2026 (USD Million)

Table 92. Adaptimmune: Company Snapshot

Table 93. Adaptimmune: Business Unit

Table 94. Adaptimmune.: Product Portfolio

Table 95. Anchiano Therapeutics: Company Snapshot

Table 96. Anchiano Therapeutics: Product Category

Table 97. Anchiano Therapeutics: Product Portfolio

Table 98. Achieve Life Sciences.: Company Snapshot

Table 99. Achieve Life Sciences.: Operating Segments

Table 100. Achieve Life Sciences: Product Portfolio

Table 101. Adverum Biotechnologies, Inc.: Company Snapshot

Table 102. Adverum Biotechnologies, Inc.: Product Category

Table 103. Adverum Biotechnologies, Inc.: Product Portfolio

Table 104. Abeona Therapeutics Inc.: Company Snapshot

Table 105. Abeona Therapeutics Inc.: Product Category

Table 106. Abeona Therapeutics Inc.: Product Portfolio

Table 107. Applied Genetic Technologies Corporation: Company Snapshot

Table 108. Applied Genetic Technologies Corporation: Operating Segments

Table 109. Applied Genetic Technologies Corporation: Product Portfolio

Table 110. Arbutus: Company Snapshot

Table 111. Arbutus: Product Portfolio

Table 112. Audentes: Company Snapshot

Table 113. Audentes: Product Portfolio

Table 114. Avexis: Company Snapshot

Table 115. Avexis: Product Portfolio

Table 116. Bluebird Bio : Company Snapshot

Table 117. Bluebird Bio: Product Category

Table 118. Bluebird Bio.: Product Portfolio

Table 119. Celgene: Company Snapshot

Table 120. Celgene: Operating Segments

Table 121. Celgene: Product Portfolio

Table 122. Crispr: Company Snapshot

Table 123. Crispr: Product Portfolio

Table 124. Editas.: Company Snapshot

Table 125. Editas: Product Portfolio

Table 126. Gilead: Company Snapshot

Table 127. Gilead: Operating Segments

Table 128. Gilead: Product Portfolio

Table 129. Gsk.: Company Snapshot

Table 130. Gsk: Operating Segments

Table 131. Gsk: Product Portfolio

Table 132. Intellia: Company Snapshot

Table 133. Intellia: Product Portfolio

Table 134. Merck: Company Snapshot

Table 135. Merck: Operating Segments

Table 136. Merck.: Product Portfolio

Table 137. Novartis: Company Snapshot

Table 138. Novartis: Operating Division

Table 139. Novartis: Product Portfolio

Table 140. Regenxbio: Company Snapshot

Table 141. Regenxbio: Product Portfolio

Table 142. Spark Therapeutics: Company Snapshot

Table 143. Spark Therapeutics, Inc.: Product Category

Table 144. Spark Therapeutics, Inc.: Product Portfolio

Table 145. Sangamo Therapeutics: Company Snapshot

Table 146. Sangamo Therapeutics: Operating Business Segments

Table 147. Sangamo Therapeutics: Product Portfolio

Table 148. Uniqure: Company Snapshot

Table 149. Uniqure: Product Business Segment

Table 150. Uniqure.: Product Portfolio

Table 151. Voyager.: Company Snapshot

Table 152. Voyager : Product Business Segments

Table 153. Voyager.: Product Portfolio

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Adaptimmune Therapeutics Plc., Anchiano Therapeutics Ltd., Achieve Life Sciences, Inc., Adverum Biotechnologies, Inc., Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Arbutus Biopharma Corporation, Audentes Therapeutics, Inc., AveXis, Inc., Bluebird Bio, Inc., Celgene Corporation, CRISPR Therapeutics AG, Editas Medicine, Inc., Editas Medicine, Inc., GlaxoSmithKline Plc., Intellia Therapeutics, Inc., Merck & Co., Inc., Novartis AG, REGENXBIO Inc., Spark Therapeutics, Inc., Sangamo Therapeutics, Inc., Uniqure N. V., Voyager Therapeutics, Inc.